<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632215</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 0223/09</org_study_id>
    <nct_id>NCT01632215</nct_id>
  </id_info>
  <brief_title>Preoperative Gabapentine for Carpal Tunnel</brief_title>
  <official_title>Effect of Preoperative Gabapentine for Carpal Tunnel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of S達o Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the postoperative analgesic effect of preoperative
      gabapentine for carpal tunnel syndrome surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There was studied 40 patients. Group 1 patients received 600 mg of gabapentin 1 hour before
      surgery; G2 received placebo 1 hour before surgery.

      Anesthesia was regional intravenous block. Postoperative analgesia when needed was with
      acetaminophen. If needed was administered codeine. The evaluation of neuropathic pain was
      made by DN4 questionnaire. Pain intensity was assessed by numeric scale at block and after
      30min, 1h, 2h, 2wk, 4wk, 6m. It was noted the duration of analgesia, and the amount of
      acetaminophen and codeine.

      The statistical program used for analysis of the results was the Instat Graph
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numerical score from 0 to 10; zero means no pain and 10 is the more intense pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Pain</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of neuropathic pain and complex regional syndrome pain after 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>preoperative gabapentine,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentine</intervention_name>
    <description>Gabapentine 600 mg 01 dose</description>
    <arm_group_label>preoperative gabapentine,</arm_group_label>
    <other_name>Anticonvulsant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Sugar pill 01 dose</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  carpal tunnel syndrome

        Exclusion Criteria:

          -  disorientation, psychiatric disease, myocardial ischemia, hypertension, arrhythmia,
             another pain syndrome, drug user, and pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rioko K Sakata, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal de S達o Paulo</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2012</firstreceived_date>
  <firstreceived_results_date>February 24, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of S達o Paulo</investigator_affiliation>
    <investigator_full_name>Rioko Kimiko Sakata</investigator_full_name>
    <investigator_title>Pain Clinic Director</investigator_title>
  </responsible_party>
  <keyword>gabapentine</keyword>
  <keyword>postoperative pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Preoperative Gabapentine,</title>
          <description>Gabapentine
Gabapentine: Gabapentine 600 mg 01 dose</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo group
Sugar pill: Sugar pill 01 dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preoperative Gabapentine,</title>
          <description>Gabapentine
Gabapentine: Gabapentine 600 mg 01 dose</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo group
Sugar pill: Sugar pill 01 dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>gabapentine 51,5 (41 - 59) Sugar pill 52,1 (35 - 70)</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.5" lower_limit="41" upper_limit="59"/>
                <measurement group_id="B2" value="52.1" lower_limit="35" upper_limit="70"/>
                <measurement group_id="B3" value="51.8" lower_limit="35" upper_limit="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Pain</title>
        <description>Number of neuropathic pain and complex regional syndrome pain after 6 months</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity</title>
        <description>Numerical score from 0 to 10; zero means no pain and 10 is the more intense pain</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gabapentine,</title>
            <description>Gabapentine
Gabapentine: Gabapentine 600 mg 01 dose</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo group
Sugar pill: Sugar pill 01 dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Intensity</title>
            <description>Numerical score from 0 to 10; zero means no pain and 10 is the more intense pain</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="0.8"/>
                  <measurement group_id="O2" value="0.4" spread="1.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Preoperative Gabapentine,</title>
          <description>Gabapentine
Gabapentine: Gabapentine 600 mg 01 dose</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo group
Sugar pill: Sugar pill 01 dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rioko K. Sakata</name_or_title>
      <organization>Federal University of S達o Paulo</organization>
      <phone>055 11 5084 7463</phone>
      <email>riokoks.dcir@epm.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
